Research ArticleClinical Studies
Potential Risk Factors for Nivolumab-induced Thyroid Dysfunction
HARUHIKO YAMAZAKI, HIROYUKI IWASAKI, TOSHINARI YAMASHITA, TATSUYA YOSHIDA, NOBUYASU SUGANUMA, TAKASHI YAMANAKA, KATSUHIKO MASUDO, HIROTAKA NAKAYAMA, KAORI KOHAGURA, YASUSHI RINO and MUNETAKA MASUDA
In Vivo November 2017, 31 (6) 1225-1228;
HARUHIKO YAMAZAKI
1Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Yokohama, Japan
HIROYUKI IWASAKI
1Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Yokohama, Japan
TOSHINARI YAMASHITA
1Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Yokohama, Japan
TATSUYA YOSHIDA
1Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Yokohama, Japan
NOBUYASU SUGANUMA
1Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Yokohama, Japan
TAKASHI YAMANAKA
1Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Yokohama, Japan
KATSUHIKO MASUDO
2Department of Breast and Thyroid Surgery, Yokohama City University Medical Center Minamiku, Yokohama, Japan
HIROTAKA NAKAYAMA
3Department of Surgery, Yokohama City University School of Medicine, Yokohama, Japan
KAORI KOHAGURA
3Department of Surgery, Yokohama City University School of Medicine, Yokohama, Japan
YASUSHI RINO
3Department of Surgery, Yokohama City University School of Medicine, Yokohama, Japan
MUNETAKA MASUDA
3Department of Surgery, Yokohama City University School of Medicine, Yokohama, Japan
In this issue
In Vivo
Vol. 31, Issue 6
November-December 2017
Potential Risk Factors for Nivolumab-induced Thyroid Dysfunction
HARUHIKO YAMAZAKI, HIROYUKI IWASAKI, TOSHINARI YAMASHITA, TATSUYA YOSHIDA, NOBUYASU SUGANUMA, TAKASHI YAMANAKA, KATSUHIKO MASUDO, HIROTAKA NAKAYAMA, KAORI KOHAGURA, YASUSHI RINO, MUNETAKA MASUDA
In Vivo Nov 2017, 31 (6) 1225-1228;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor Efficacy
- Association Between Immune-related Adverse Events and Clinical Outcome Following Nivolumab Treatment in Patients With Metastatic Renal Cell Carcinoma
- The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Disorders
- Efficacy and Toxicity of Pembrolizumab in Pediatric Metastatic Recurrent Melanoma








